Skip to main content
TipRanks
Go Ultimate75% OFF

Anika Therapeutics (AKP) Q3 2026 Earnings Report

0 Followers

DE:AKP Q3 2026 EPS Results

Actual EPS
EUR 0.26
Consensus EPS
EUR 0.38
Beat/Miss
Missed by -EUR 0.12
One Year Ago EPS
EUR 0.04

DE:AKP Q3 2026 Revenue Results

Actual Revenue
EUR 27.65M
Expected Revenue
EUR 26.61M
Beat/Miss
Beat by +EUR 1.05M
YoY Revenue Growth
+9.98%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/06/2026
Time
Before Open
Conference Call
Friday, November 6, 2026
DE:AKP Upcoming Earnings

Anika Therapeutics's next earnings date is estimated for March 4, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

DE:AKP Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 06, 2026|% Change Since:-36.67%|
Earnings Call Sentiment|Positive

The call was predominantly positive, with 10% third-quarter revenue growth, record commercial revenue, strong Integrity performance, improved year-over-year gross margin and profitability, higher 2026 guidance, a favorable long-term Boehringer agreement, and meaningful manufacturing and CINGAL milestones. Offsetting concerns included softer U.S. elective surgery activity, a lower commercial growth outlook, expected 2027 U.S. pricing declines, lower year-to-date operating cash flow, and the HYALOFAST PMA being deemed not approvable. Highlights significantly outweighed the lowlights.

Company Guidance

For 2026, Anika raised total company revenue growth guidance to 6% to 10% from 5% to 10%, expects OEM channel revenue growth of 5% to 9% from 0% to 5% previously, and expects commercial channel growth of 9% to 13% from 12% to 18% previously; adjusted EBITDA margin guidance increased to 15% to 17% from 13% to 17%. For 2027, total company revenue growth is reaffirmed at flat to 5%, commercial channel revenue growth was corrected to 5% to 15%, and OEM revenue is expected to be flat to modestly lower, with pricing declines embedded in guidance; forward guidance does not include any US HYALOFAST sales. The 2026 adjusted EBITDA impact from investment in regenerative solutions is now expected to be closer to $8 million versus $10 million previously, and the company expects positive operating cash flow in the fourth quarter, with CapEx investments in the fourth quarter and next year. The CINGAL NDA is expected to be submitted before year-end 2027, with the bioequivalence study report expected in the first quarter of 27; the Hyvisc agreement is expected to provide $8 million in payments, including a $4 million upfront payment expected in the first quarter of 2027 and the remaining $4 million tied to commercial volumes.

  • Third-Quarter Revenue GrowthTotal revenue increased 10% to $30.6 million from $27.8 million, with growth in both the commercial and OEM channels.
  • Commercial Channel Reached Record RevenueCommercial channel revenue grew 17% to $14 million, the highest commercial channel revenue in company history. International OA pain management revenue increased 19%, supported by CINGAL and MONOVISC, while total regenerative solutions revenue grew 12%.
  • Strong Nine-Month Channel PerformanceThrough the first nine months, commercial channel revenue was up 15% and OEM channel revenue was up 11%.
  • Integrity Continued Rapid GrowthIntegrity revenue grew more than 30% year over year, increased sequentially, and reached 37% growth year to date. The product generated $7 million in revenue over the trailing 12 months entering the fourth quarter.
  • Integrity Platform ExpansionLarger implant sizes expanded Integrity use into foot and ankle and knee procedures in addition to shoulder applications. Second-generation instrumentation launched in September, providing an alternative insertion and deployment option to address surgeon preferences. The company also reported strong reuse among key surgeons and a rebound at the beginning of the fourth quarter.
  • OEM Channel Growth and Higher OutlookOEM revenue increased 5% to $16.6 million in the quarter and grew 11% through the first nine months, supported by continued execution with J&J and non-orthopedic products. The company increased its full-year OEM outlook to reflect a greater contribution from the channel.
  • Ten-Year Boehringer Ingelheim AgreementAnika entered into a new 10-year distribution agreement with its existing Hyvisc partner, Boehringer Ingelheim. The agreement includes higher transfer pricing, a royalty on end-market sales, higher contractual minimum purchases, and $8 million in expected payments, including a $4 million upfront payment expected in the first quarter of 2027 and $4 million tied to commercial volumes.
  • HYALOMATRIX Reintroduced Through OEM ChannelHYALOMATRIX, Anika's HYAFF wound product, was reintroduced in the U.S., with the first commercial units shipped to a new OEM distributor during the third quarter.
  • Year-Over-Year Gross Margin ImprovementGross margin improved to 62% from 56% a year ago, reflecting progress in manufacturing execution, productivity, and operational improvements.
  • Manufacturing Capacity and Process ImprovementsThe company received FDA approval for a new aseptic manufacturing process and validated a second crosslink filler. Unit volumes on the crosslink line were more than 50% higher than 2022 levels, and Anika is increasing production and building safety stock to support demand.
  • Improved Profitability MetricsGAAP operating loss narrowed to $700 thousand from $3.2 million. GAAP loss from continuing operations narrowed to $300 thousand, or $0.02 per diluted share, from $3.2 million, or $0.22 per diluted share. Adjusted net income from continuing operations was $3.9 million, or $0.29 per diluted share, and adjusted EBITDA increased to $5.1 million from $900 thousand a year ago.
  • Disciplined Expense ManagementTotal operating expenses increased 4% to $19.5 million. Research and development expense was $7.9 million versus $6.9 million, while selling, general, and administrative expense declined to $11.7 million. G&A excluding stock-based compensation was down 19% year over year. The expected 2026 adjusted EBITDA impact from investment in regenerative solutions was reduced from $10 million to closer to $8 million as a result of disciplined expense management and regional talent alignment.
  • Strong Quarterly Cash PositionAnika generated $8.4 million of operating cash flow in the quarter and invested $1.7 million in capital expenditures. Cash and cash equivalents increased to $45 million at the end of September from $38.4 million at the end of June.
  • CINGAL Development MilestonesThe company completed enrollment in the CINGAL bioequivalence study in September, earlier than its previously communicated year-end target, and expects the study report in the first quarter of 2027. Anika expects to submit the CINGAL NDA before the end of 2027 and is progressing the CMC work required to file the product as a drug.
  • Raised 2026 Revenue and Adjusted EBITDA Margin GuidanceFull-year 2026 total company revenue growth guidance was raised to 6% to 10% from 5% to 10%, and adjusted EBITDA margin guidance was raised to 15% to 17% from 13% to 17%. The company expects OEM revenue growth of 5% to 9%, compared with 0% to 5% previously.
  • Continued Investment in Growth and CapacityAnika plans to continue investing in capital expenditures, manufacturing capacity, its regenerative solutions team, commercial capabilities, and its clinical, manufacturing, and quality programs. New international frontline commercial team members are being added in a cost-neutral way.
  • Ongoing HYAFF Innovation PipelineThe company continues to advance preclinical studies of HYAFF fiber for regenerative suture and tape and said it remains encouraged by the data from those studies.

DE:AKP Earnings History

DE:AKP earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 04, 20272026 (Q4)0.12-0.28――
Nov 06, 20262026 (Q3)0.380.260.04625.00% (+0.23)
Jul 29, 20262026 (Q2)0.030.38-0.12423.08% (+0.50)
Apr 29, 20262026 (Q1)0.000.24-0.05550.00% (+0.30)
Feb 26, 20262025 (Q4)-0.110.28-0.031133.33% (+0.31)
Nov 05, 20252025 (Q3)-0.160.04-0.23116.00% (+0.26)
Jul 30, 20252025 (Q2)-0.24-0.120.15-176.47% (-0.27)
May 09, 20252025 (Q1)-0.08-0.050.08-166.67% (-0.14)
Mar 12, 20252024 (Q4)-0.20-0.030.05-160.00% (-0.07)
Oct 31, 20242024 (Q3)0.08-0.230―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed